摘要
目的研究长春瑞滨联合顺铂（NP方案）对蒽环类耐药转移性乳腺癌治疗疗效与不良反应。方法对符合标准的45例蒽环类耐药转移性乳腺癌患者给予长春瑞滨联合顺铂方案治疗，长春瑞滨25mg／m^2静脉推注，d1、8，顺铂30mg／m^2静脉滴注，d1～3，每3周重复1次。治疗2个周期以上，对其有效率及不良反应进行分析。结果全组45例共完成120个周期的治疗，中位数为4个周期，均可评价疗效。有效率为64．4％，其中完全缓解7例，部分缓解22例，稳定11例，进展5例。不良反应主要为骨髓抑制及胃肠道反应。结论长春瑞滨联合顺铂方案治疗转移性乳腺癌经初步观察有一定的疗效，其不良反应患者可以耐受。值得临床推广和进一步研究。
Objective To evaluate the efficacy and toxicity of navelbine（NVB） combined with cisplatin（DDP） treatment for me tastatic breast cancer who had failed to anthracycline based chemotherapy. Methods Fourty-five patients of metaslatic breast canc er received NVB 25 mg/m^2 ,iv,d1,8 combined with DDP 30 mg/m^2 i. vdrip,d1-3 and repeated every 3 weeks. All enrolled patients recerved at least 2 cycles of treatment. Results Overall 120 cycles were given to the/15 patients enrolled into the study（mean 4）. All could be evaluated. The response rate was 64. 4%, seven patients achieved complete response（CR）, twenty two patients a chieved partial （PR）, eleven patients achieved stable disease（SD）, and five patients achieved progressive disease（PD）. The major side effects were bone marrow suppression and gastrointestinal effects. Conclusion The combined chemotherapy of Navelbine plus Cisplatin is effective and safe in the treatment of failed to anthracycline based chemotherapy on metastatic breast cancer breast cancer. It is deserved to be spreaded and applicated.
出处
《重庆医学》
CAS
CSCD
北大核心
2010年第7期815-816,828,共3页
Chongqing medicine
关键词
长春瑞滨
顺铂
乳腺癌
navelbine
oisplatin
breast cancer
